1. In Vivo
  2. >>Business Strategy

Creating Your Own Customers

Forward integration into the service sector may be right for a select number of medical product companies, but many such mergers fail. Services require dramatically different core competencies and prospective customers may view the product company as a competitor. The few successes highlight the strategies' hurdles.

Until the early 1980s, almost all kidney dialysis patients received hemodialysis in centers. There, large equipment cleansed their blood in dialyzers outside their bodies. But in the 1970s, Baxter International Inc. developed a system to free some dialysis patients from their machines. Its continuous ambulatory peritoneal dialysis (CAPD) system utilizes the patient's own peritoneal membrane inside his body as the semipermeable barrier through which blood can be filtered. In the convenience of the patient's home, dialysis solution is introduced through a catheter into the patient's peritoneal cavity. Toxins collect in the solution, which is then withdrawn from the patient through the same catheter.

Baxter's first CAPD kit was approved in 1979. The problem: this innovative product was ahead of its time, with no...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.